Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2002

View Archived Issues

New data on the efficacy and safety of CTLA4Ig in rheumatoid arthritis

Novel cathepsin K inhibitors with utility in osteoporosis

Extensive coverage of adalimumab at ACR meeting

Modulators of neurotransmitter receptors identified at Sepracor

Series of PDE5 inhibitors in early development at Tanabe Seiyaku

Compounds for increasing GLP-1 blood levels designed at Banyu

Icos researchers identify novel inhibitors of CHK1 kinase for use as chemosensitizers

Novel vectorized opioid analgesics under study at Synt:em

CuraGen establishes collaboration with Mitsubishi in schizophrenia

Phase IIa results show early signs of clinical activity for GCS-100 in pancreatic cancer

Genta and Aventis initiate two clinical trials with Genasense

Genzyme initiates kidney cancer clinical trial with innovative vaccine

FXR agonist has beneficial effects in rat model of hepatic injury

New data on the efficacy of darbepoetin alfa in cancer-related anemia

Mechanism of anti-HBV activity of AT-130 described at AASLD meeting

Inhibitors of PDE4 with cognition-enhancing and antidepressant profile

Etoricoxib reported to be superior to naproxen in rheumatoid arthritis

Potential use of nuclease-stabilized ribozymes in chronic HCV infection

NicOx and AstraZeneca select another CINOD development candidate

Novel, orally active neuroprotective agent from natural sources

Novel VR1 antagonist effective in rat models of chronic pain

Crestor receives first approval in Europe

AstraZeneca announces trade name Galida for its investigational drug tesaglitazar

GW Pharmaceuticals announces positive results from phase III trials with cannabis-based medicines

Phase II trials initiated with novel anticoagulant rNAPc2

First patient enrolled in prostate cancer trial with Norelin

Teva announces termination of Copaxone trial in primary progressive multiple sclerosis patients

Eisai submits MAA for Aricept

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...